VitalConnect Secures over $30 Million in Oversubscribed Series F Financing

VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed Series F financing in excess of $30 million. The financing round was led by Revelation Partners with significant participation from the company’s existing investors, including Pacific General Ventures and EW Healthcare Partners.

Thoma Bravo Announces Strategic Growth Investment in Bluesight to Support the Company’s Acquisition of Medacist

Thoma Bravo, a leading software investment firm, today announced the closing of a strategic growth investment in Bluesight, the Medication Intelligence™ Company. The investment is expected to further enhance Bluesight’s drug diversion prevention offerings through its acquisition of Medacist, a pioneer in drug diversion monitoring, and continue to grow Bluesight’s inventory management and spend optimization offerings. 

Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain

Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), announced today that it has raised $26 million in an oversubscribed Series C equity funding round. The financing was led by new investor Norwest Venture Partners with participation from existing investors including Pitango Venture Capital.

Arcadia Raises $125 Million in New Financing from Vista Credit Partners

Arcadia (Arcadia.io), a leading data analytics platform for healthcare, today announced $125 million in financing from Vista Credit Partners, the credit-lending arm of Vista Equity Partners and a strategic investor and financing partner focused on the enterprise software, data and technology market.

General Atlantic Leads $179M Growth Investment into Gravie

Gravie, one of the fastest growing employer health benefits companies in the United States, announced today that General Atlantic, a leading global growth equity investor, will anchor a $179 million equity investment into the Company, alongside participation from existing Gravie investors FirstMark Capital and AXA Venture Partners.